Background. Ductal carcinoma in situ (DCIS) can be a precursor to invasive breast cancer. Since the advent of screening mammography in the 1980's, the incidence of DCIS has increased dramatically. The value of screen detection and treatment of DCIS, however, is a matter of controversy, as it is unclear the extent to which detection and treatment of DCIS prevents invasive disease and reduces breast cancer mortality. The aim of this paper is to provide an overview of existing Cancer Intervention and Surveillance Modelling Network (CISNET) modeling approaches for the natural history of DCIS, and to compare these to other modeling approaches reported in the literature. Design. Five of the 6 CISNET models currently include DCIS. Most models assume that some, but not all, lesions progress to invasive cancer. The natural history of DCIS cannot be directly observed and the CISNET models differ in their assumptions and in the data sources used to estimate the DCIS model parameters. Results. These model differences translate into variation in outcomes, such as the amount of overdiagnosis of DCIS, with estimates ranging from 34% to 72% for biennial screening from ages 50 to 74 y. The other models described in the literature also report a large range in outcomes, with progression rates varying from 20% to 91%. Limitations. DCIS grade was not yet included in the CISNET models. Conclusion. In the future, DCIS data by grade from active surveillance trials, the development of predictive markers of progression probability, and evidence from other screening modalities, such as tomosynthesis, may be used to inform and improve the models' representation of DCIS, and might lead to convergence of the model estimates. Until then, the CISNET model results consistently show a considerable amount of overdiagnosis of DCIS, supporting the safety and value of observational trials for low-risk DCIS.
also remain indolent for sufficiently long that a woman dies of other causes. [5] [6] [7] The proportion of untreated DCIS that will progress to invasive breast cancer is unknown, 1 and therefore, the impact of detecting and treating DCIS, particularly for any given woman, is unclear. Treating some DCIS lesions will probably prevent invasive disease and, consequently, might reduce breast cancer mortality; thus, in these cases, it would be considered a benefit. Other lesions, however, might remain indolent in the absence of treatment, with only harms related to the treatment of these lesions (representing overdiagnosis and overtreatment). Because we do not know which and how many DCIS lesions will progress, the value of screen detection and treatment of DCIS remains unknown and is a matter of considerable controversy.
Despite the uncertainty around the natural history of DCIS, some predictors for progression have been identified. For example, younger age at diagnosis and black ethnicity are associated with higher breast cancer-specific mortality among patients with DCIS. 8, 9 Other identified factors for progression include estrogen receptor (ER)-negative status, larger DCIS tumor size, and comedonecrosis. 9 In addition, DCIS progression to invasive breast cancer can be predicted by cytologic grade. 5, 7, 9 Pathologists use 3 grading categories corresponding to well (grade 1), moderately (grade 2), and poorly (grade 3) differentiated DCIS; 10 also referred to as ''low grade'', ''intermediate grade'', and ''high grade'', respectively. Grade is associated with recurrence 11, 12 and the survival benefit of surgical treatment is said to be lower for lowgrade DCIS than for intermediate-or high-grade DCIS. 13 Furthermore, the DCIS Score, based on Oncotype DX, is associated with recurrence of DCIS (either as DCIS or invasive breast cancer). 14 These identified prognostic factors for recurrence may enable physicians to tailor treatment strategies. Specifically, recommending treatment that is less aggressive would be appropriate for DCIS that has a low risk for future recurrence, and predictors such as age, ER status, and/or grade might be used to identify such low-risk lesions. Thus, understanding the natural history of DCIS and its recurrence and progression predictors to guide treatment strategies is important for both clinical and public health decisions. However, given that progression paths are not directly observable investigating the natural history of DCIS is difficult because of a lack of highquality data. In addition, data are also limited because survival for women diagnosed with DCIS is very high and a trial would need to enroll high numbers of women and follow them for a lifetime to be adequately powered to detect an impact of screening and treatment on mortality or other endpoints. Moreover, the natural history of DCIS is difficult to study because the standard of care is immediate treatment following diagnosis. In these instances, (comparative) modeling can be useful; for example, to provide a range of plausible DCIS progression and regression rates by evaluating what set of assumptions about these rates best fit the existing observable data. In addition, in natural history models, the difference in risk of the progression based on age, grade, and ER status can be included by allowing varying transition rates for these factors, which has already been done in a well-established microsimulation model to include grade. 15 Furthermore, within the Cancer Intervention and Surveillance Modelling Network (CISNET) comparative modeling work has been done. Previously, 3 CISNET models estimated the amount of DCIS overdiagnosis in women aged 74 y and older. The results indicated that, at older ages, harms began to outweigh the benefits, largely because of the increasing amount of overdiagnosis of DCIS at older ages, 16 which is partly due to the higher death rate from competing causes with aging. Together, these modeling papers on the one hand highlight the uncertainty regarding the natural history of DCIS but also show the potential value of modeling in providing information where results are consistent.
The aim of this paper is to provide an overview of the ways CISNET models simulate the natural history of DCIS, illustrate how different assumptions affect results, compare the CISNET models to other models described in the literature, and highlight developments that might lead to model improvements or refinements.
CISNET Models CISNET DCIS Models -Model Overview
CISNET is a consortium of the National Cancer Institute (NCI)-sponsored investigators who use statistical modeling to improve our understanding of cancer control interventions in prevention, screening, and treatment and their effects on population trends in incidence and mortality. The CISNET breast models have been described in detail previously and recently updated descriptions have been given. [17] [18] [19] [20] [21] [22] Briefly, the models are designed to match breast cancer incidence and mortality rates observed in the US. Four models are microsimulation models ( (https://resources.cisnet.cancer.gov/registry/sitesummary/breast/). Five of the 6 CISNET models currently include DCIS (all except model S). Most models assume that some, but not all, lesions progress to invasive cancer; for example, by including 3 different types of preclinical DCIS: DCIS that progresses to invasive disease during the preclinical phase, progressive DCIS that is diagnosed clinically, and DCIS that does not progress (and might regress). However, the models differ in natural history of DCIS (Table 1) and model structure (see Figure 1) , with different pathways for the progression and regression of DCIS and breast cancer. For example, invasive cancer can either develop through pre-clinical, screen-detectable DCIS ( Figure 1C ), or also develop directly from pre-clinical DCIS that is not detectable at screening ( Figure 1A and 1B) . In the models, DCIS can regress from pre-clinical, screen-detectable DCIS to preclinical undetectable DCIS ( Figure 1A) or to an absorbing ''no breast cancer'' state and disappear (''cease to exist'') ( Figure 1B and 1C) . One model (model W) allows regression of pre-clinical DCIS as well as invasive disease ( Figure 1D ). Although the regression of breast cancer, especially invasive disease, is controversial, there is some evidence supporting the possibility of regressing tumors, including epidemiological evidence 23 and a case report on the regression of breast cancer on imaging. 24 Most of the CISNET models have used data from the Surveillance, Epidemiology, and End Results (SEER) Program, 25 typically age-specific incidence over time, combined with data from other sources (Wisconsin cancer registry for model W, Dutch data for model E) to estimate DCIS parameters; although, one model used data from another source (Norwegian data for model D). 26 All CISNET models include a certain probability for mammography to detect DCIS at screening (Table  2) . Specifically, models D and GE use the same detection mechanism for DCIS as for invasive disease by including a sensitivity of screening. Model W uses the detection probability as a function of tumor size and because in situ lesions are small, the likelihood of detecting DCIS is lower than that for detecting invasive breast cancer. Model E includes 2 separate detection mechanisms; DCIS detection is modeled by including a sensitivity, whereas screen-detection of invasive disease is modeled by a threshold diameter. Thus, in some models the sensitivity of a screening test differs for DCIS and invasive cancer.
CISNET Models: Analysis
The CISNET models were recently applied to evaluate screening outcomes of various screening strategies differing by the age at which screening starts (40, 45, or 50 y) and screening interval (annual, biennial) for the US female population. 27 We assessed the results of those prior analyses by focusing on the (as yet unpublished) model-specific rates of DCIS detection and overdiagnosis of the 5 CISNET models that include DCIS. 28 Overdiagnosis was defined as the detection of tumors that would not have been detected in a woman's lifetime in the absence of screening. We estimated the detection and overdiagnosis rate per 1000 women screened followed from the age 40 y over their lifetimes. In addition, the percentage overdiagnosis was calculated by dividing the rate of overdiagnosed DCIS by the rate of detected DCIS. We focus on 4 screening scenarios: biennial screening from 50 to 74 y (base), more frequent screening (annual screening from ages 50 to 74 y; A50-74), an earlier starting age (biennial screening from ages 40 to 74 y; B40-74), and later stopping age (biennial screening from ages 50 to 84 y; B50-84).
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CISNET Models: Results and Implications
For biennial screening between ages 50 and 74 y, the 5 models that include DCIS predict that 154.4 women (median; range across 5 models 137.4 to 158.5; (Table 3 ). In contrast, for invasive disease, the models estimate that, of the 128.2 (110.7 to 131.8) breast cancers detected, 3.3 (1.8 to 15.4) are overdiagnosed, corresponding to 2.6% (1.5% to 12.0%; Table 3 ). This means that 2.6% (1.5% to 12.0%) of the invasive breast cancers that are detected would not have been detected in the absence of screening and are overdiagnosed. There is no direct connection between the amount of overdiagnosis of DCIS and overdiagnosis of invasive disease in the models. For example, one model predicts relatively low overdiagnosis percentages for DCIS as well as invasive breast cancer (model GE), whereas another model predicts relatively high percentages for both (model M). In contrast, there are also models that have modest estimates of DCIS overdiagnosis combined with relatively high estimates of invasive disease overdiagnosis (model W) or the other way around (model E). When annual screening from ages 50 to 74 y is simulated, the models estimate 0.1 to 14.0 additional cases of DCIS being detected, of which 0.1 to 13.7 are overdiagnosed (Table 4) . Also, the models differ for the source for additional DCIS cases. For Models D and M, the increase in the detection of DCIS is entirely overdiagnosis, whereas, in models E, GE, and W, it is combination of overdiagnosis and earlier detection of lesions with progressive potential. 
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In addition, the order of scenarios that have the largest increase in overdiagnosis of DCIS varies across models, as well as the magnitude of the increase. For example, for annual screening, the increase in overdiagnosis varies between 0.1 and 13.7 overdiagnosed DCIS cases across models. Some models estimate the largest change in detection and overdiagnosis when annual screening is considered (models E, M, and W), whereas other models predict the largest increase when the upper age of screening is extended to age 84 y (models D and GE).
For the biennial screening scenario from ages 50 to 74 y, the highest percentage of overdiagnosis of DCIS and invasive breast cancer was estimated by model M followed by model W. This can be explained by the modeling choice of model M to assume a rather stable trend in breast cancer incidence (background trend) over time and, therefore, assign more of the increase to overdiagnosis than do other CISNET models. Model W assumes that some invasive disease is non-progressive, and consequently, has a higher estimate for overdiagnosis than the other 3 models, especially for invasive disease.
For the other scenarios-annual screening from ages 50 to 74 y, biennial screening from ages 40 to 74 y, and biennial screening from ages 50 to 84 y-there are 2 clusters of models: models D and M assign the increase in detection of DCIS when screening more intensively entirely to overdiagnosis. For model M, this is again related to the stable background trend, whereas for model D, the screen-detectable period for DCIS is relatively short. The other 3 models (models E, GE, and W) only assign a proportion of the increase to overdiagnosis and a proportion to earlier diagnosis. Models E and GE assign most of the increase to overdiagnosis when moving to older ages and a smaller percentage when moving to younger ages.
Literature

Description of Other DCIS Models in the Literature
To improve the understanding of the natural history of DCIS, we conducted a literature search to identify DCIS models that have been described in the literature. We searched PubMed and JSTOR for ''DCIS natural history modeling'' and ''DCIS progression'', and selected the articles that focus on the estimation of key DCIS natural van Ravesteyn et al. 131S
history parameters, such as mean sojourn time for screen-detectable pre-clinical DCIS, and the percentage of DCIS cases that progress to either invasive cancer, clinical DCIS, or potentially regress. We identified 10 relevant studies, of which 9 include DCIS natural history modeling (Table 5 ). Among them, 4 studies use Markov models [29] [30] [31] [32] and 5 use simulation models, 15,33-36 with parameters estimated with either maximum likelihood, Bayesian Gibbs sampling or least square methods, and varying assumptions about DCIS natural history pathways. Seven studies assumed that all invasive breast cancers progress through a pre-clinical in situ or DCIS state that can be detected at screening, 15, 29, [32] [33] [34] 36 whereas the other 2 studies assumed that some DCIS or in situ lesions first become visible on mammograms as small invasive tumors. 30, 35 DCIS or in situ is assumed to have both progressive and non-progressive paths in 8 studies, 15, [29] [30] [31] [32] [33] [34] 36 with 1 study also including non-progressive invasive cancers. 36 These 10 studies used various data sources including different combinations of 1) data aggregated from population registries; 15, 30, 35, 36 2) observed national screening service program data; 32, 33, 37 3) detailed data from randomized screening trials; 29,31,32,34 and 4) estimates made from previously reported studies, including studies of DCIS first overlooked at mammography. 30, 36 Generally, more detailed screening data makes it possible to deduce more realistic natural history models, fitting the model using data from different screening rounds and screening histories. 29, 32 In addition to the different data sources, 3 studies include all in situ lesions, 29 
Parameters in the Literature Useful for DCIS Modeling
The estimated proportion of DCIS progressing to invasive cancer varies widely in the literature (Table 5) , mainly due to the available data, study-specific model assumptions, and different model structures. When all invasive breast cancer is assumed to go through a preclinical, screen-detectable DCIS state, the estimated progression rate of DCIS to invasive varies from 61% to 91%. 15, 29, [31] [32] [33] [34] 36 When this assumption is not made, the estimated progression rate from DCIS to invasive varies from 20% to 24.4%. 30, 35 Some studies report a large proportion of progressive DCIS, 31, 33, 34, 36 whereas other studies report that most DCIS cases do not progress to invasive cancer. 30, 35 When the proportion of progressive DCIS is reported by screening round, the subsequent screening rounds often reported smaller proportions of progressive DCIS 29, 32 compared with the initial screening, as cases with a long sojourn time were diagnosed in earlier screening exams. High-grade DCIS cases have a larger proportion progressing to invasive than low-grade DCIS cases. 15 As for the mean sojourn time, when all invasive cancers are assumed to be screen detectable at a pre-clinical DCIS stage, the estimated mean sojourn time for progressive DCIS cases in the pre-clinical, screen-detectable DCIS state are usually short, varying from 1 mo to 5 y. 29, 31, 32, 34, 35 On the other hand, the sojourn time estimates are much longer if it is assumed that only a small fraction of invasive cancers comes from pre-clinical, screen-detectable DCIS. 30 The estimated mean sojourn time in pre-clinical, screen-detectable DCIS state for DCIS cases that progress to clinical DCIS or regress is typically longer than the mean sojourn time of DCIS cases that progress to invasive cancer. 29, 32 The mammography sensitivity for DCIS varies from 40% to 99%. 29, 31, 33, 34 The mean sojourn time for progressive DCIS in the pre-clinical, screen-detectable DCIS state tends to be smaller when mammography sensitivity is high. These variations reveal the uncertainty regarding the natural history of DCIS, highlighting the need and potential directions of CISNET modeling.
Discussion
Whereas the CISNET models have generated comparable results and conclusions in most other respects, DCIS detection rates and overdiagnosis reveal more variation in results, with predicted DCIS incidence ranging from 25.8 to 32.3 per 1000 women aged 40 y followed over their lifetimes, and estimates of DCIS overdiagnosis ranging from 34% to 72% for biennial screening from ages 50 to 74 y. The large difference in the predicted amount of overdiagnosis of DCIS between the models likely reflects the continued uncertainty about DCIS natural history, particularly the progression rates, which is also reflected in the results from other models described in the literature, with reported progression rates varying from 20% to 91%.
In the literature outside CISNET, several approaches have been proposed to model DCIS. The variations in model structure, assumptions and results make it challenging to deduce good overall estimates of key natural history parameters. Given the uncertainties in the DCIS models, a realistic approach to DCIS modeling is to adopt several plausible sets of model parameters and to evaluate a range of outcomes generated from the models. The CISNET models are well-suited for this type of analysis. CISNET models can project long-term implications for DCIS assumptions in terms of breast cancer outcomes, such as life expectancy and overdiagnosis, and can thus assess how much early detection impacts breast cancer mortality. Also, moving forward, CISNET models can utilize multiple models and vary model parameters to more systematically explore the impact of different DCIS assumptions on outcomes. In addition, both the impact of screening and treatment on DCISrelated outcomes can be systematically reviewed and compared. Although it remains to be seen to what extent these analyses will provide sufficiently accurate and consistent findings to inform clinical practice, the comparative modeling effort of the CISNET models will likely contribute to a greater understanding of DCIS.
Despite the large difference in the predicted amount of overdiagnosis of DCIS between models, all models indicated that the amount of overdiagnosis of DCIS is substantial (i.e., 34% to 72% for biennial screening from ages 50 to 74 y), indicating that, of the 1000 women followed over their lifetimes, 9 to 19 are overdiagnosed with DCIS and most of those women will undergo treatment for their non-invasive disease. Almost all women (98%) diagnosed with DCIS undergo a surgical procedure 13, 38 and recent work found an increase in the utilization of mastectomy with reconstruction and contralateral riskreducing mastectomy over time. 39 There was also an increase in the proportion of women undergoing adjuvant radiation therapy after surgery from 58.5% in 1998-1999 to 70% in 2006-2011. 39 Modeling estimates might improve, and the results might converge when new data becomes available. A unique opportunity to improve DCIS natural history van Ravesteyn et al. 133S Ranges present values estimated from different studies or data sources unless otherwise specified.
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modeling comes from trials on active surveillance. Several trials are currently underway to evaluate active surveillance approaches for DCIS. In the UK, the Low Risk DCIS Trial (LORIS) is comparing surgical excision to active surveillance without excision. 40, 41 Similarly, the European Organisation for Research and Treatment of Cancer (EORTC) has started a trial on the management of low-risk DCIS (LORD), which is a randomized, multicenter, non-inferiority trial, between standard therapy approach v. active surveillance. 42 In the US, a prospective, randomized trial-Comparing Operative to Medical Endocrine Therapy for low-risk DCIS (COMET)-has recently been funded. Women diagnosed with low-risk DCIS will be randomized to receive either guidelineconcordant care of surgical intervention, with or without radiation, or active surveillance of a mammogram every 6 months for 5 y. Patients in both trial arms are free to choose endocrine therapy. Also, in the US, several research networks, called cooperative groups, which conduct cancer clinical research primarily under the sponsorship of the NCI, are presently testing the use of neoadjuvant hormonal therapy in postmenopausal women with ER-positive DCIS before surgery; those with a complete response based on magnetic resonance imaging (MRI) will not receive additional therapy. However, it will take a long time before results are available; e.g., for LORIS, the initial results are expected in 2020 and, for LORD, the results are not expected before 2029. When they do become available, these data present a unique opportunity to validate models by comparing the model projections to the final trial data.
In the meantime, the models can be used to evaluate which assumptions most affect the outcomes. Also, data from several sources might be used and combined to compare model outcomes and see which model structure and progression rates fit the data best. For example, data from different screening modalities can inform models, as the ability to detect DCIS varies across modalities. Screening ultrasound is less likely to detect DCIS compared to mammography in the small number of controlled experiments available that make this comparison, because ultrasound is unlikely to detect micro-calcifications. MRI may be more sensitive than mammography, 43, 44 as it can detect the pathophysiological properties of DCIS, like basement membrane permeability, 45 perhaps explaining the tendency of MRI to detect intermediate and highgrade DCIS more readily than mammography. By using a set of parameters and modeling different screening modalities, it might become possible to narrow down the range of plausible progression parameters. Furthermore, data by ER and grade might be used to refine the models. Subsequently, the updated and refined models can be used to simulate active surveillance strategies and quantify the predicted outcomes for subgroups of women varying by age and with DCIS varying by grade and ER status.
Until then, the model results consistently show a considerable amount of overdiagnosis of DCIS, which increases with more frequent screening. This indicates that women undergoing regular screening with a screendetected DCIS are quite likely to be overdiagnosed. Thus, given the substantial amount of overdiagnosis estimated by the CISNET models for DCIS in general, the model results support the safety and value of observational trials for low-risk DCIS.
